Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome is considered to be the most common periodic fever syndrome in children and is characterized by recurrent, regular attacks of high fever associated with pharyngeal inflammation, aphthous stomatitis, and/or cervical lymphadenopathy ([@r1], [@r2]). Affected children typically begin having fever episodes between 1 and 5 y of age and continue to have these inflammatory attacks for 3 to 7 y until episodes spontaneously resolve ([@r3], [@r4]). Studies of family history suggest that PFAPA clusters within families, with nearly a quarter of patients with PFAPA having a family member with the disease; moreover, families of patients with PFAPA have a high prevalence of family members with recurrent aphthous stomatitis ([@r5], [@r6]). However, queries for rare variants associated with the disease have not yielded promising candidates, suggesting that PFAPA is a complex genetic disorder ([@r6]).

Aphthous ulcers and inflammation at the oropharyngeal mucosa are hallmarks not only of PFAPA but also of other disorders, including Behçet's disease and recurrent aphthous stomatitis. Behçet's disease is a systemic inflammatory disease primarily characterized by mucosal ulcers in the mouth, genital area, and gastrointestinal tract, as well as inflammatory attacks affecting the eyes, skin, joints, blood vessels, and brain. Several genome-wide association studies (GWAS) of Behçet's disease in Turkish and Japanese individuals implicate variants near or within the *IL10*, *IL23R-IL12RB2*, *CCR1-CCR3*, *STAT4*, *KLRC4*, *IL12A*, *IL1A-IL1B*, *IRF8*, *CEBPB-PTPN1*, *ADO-EGR2*, *RIPK2*, *LACC1*, and *FUT2* loci as risk factors for the disease ([@r7][@r8][@r9]--[@r10]). In addition, the major histocompatibility complex (MHC) allele *HLA-B\*51* consistently shows a strong association with Behçet's disease ([@r11]). Among individuals with *HLA-B\*51*, missense variants in *ERAP1*, which encodes a protein that trims peptides loaded onto class I MHC molecules, also confer risk for Behçet's disease ([@r8]). In aggregate, these risk loci suggest that the pathogenesis of Behçet's disease involves a complex interplay of aberrant innate immune and T cell responses to microbial antigens and disrupted barrier function at mucosal surfaces. Interestingly, a recent GWAS of recurrent aphthous stomatitis in the United States and United Kingdom also revealed variants near genes previously associated with Behçet's disease, including those near *IL12A*, *STAT4*, *IL10*, and *CCR1* ([@r12]). Although several statistically significant class I and class II *HLA* allele associations were identified, the most significantly associated allele, *HLA-DRB1\*01:03*, is of low prevalence among individuals of European ancestry.

In light of the phenotypic similarities among Behçet's disease, recurrent aphthous stomatitis, and PFAPA, we hypothesized that these diseases may also have genotypic overlap and screened three cohorts of patients with PFAPA for variants previously associated with Behçet's disease or recurrent aphthous stomatitis. We identified common variants associated with PFAPA and tested their functional significance with in vitro cellular assays. In addition, we discovered class I and class II classical *HLA* alleles that are risk factors for PFAPA.

Results {#s1}
=======

Common Variants Associated with PFAPA Syndrome. {#s2}
-----------------------------------------------

We selected six single nucleotide polymorphisms (SNPs) previously associated with Behçet's disease (near or within the *IL12A*, *IL10*, *STAT4*, *CCR1-CCR3*, *IL23R-IL12RB2*, and *FUT2* loci) because these are among the strongest susceptibility loci found in Turkish cohorts that also have minor allele frequency greater than 5% ([@r7][@r8]--[@r9]). Three of the variants we selected were also found to be in strong linkage disequilibrium (LD) with those associated with recurrent aphthous stomatitis (*IL12A*, *IL10*, and *STAT4*) ([@r12]). The *CCR1-CCR3* variant we selected is associated with Behçet's disease, but several nearby SNPs that are not in LD are reported to be significantly associated with recurrent aphthous stomatitis ([@r8], [@r12]). Four of the variants we selected are in noncoding regions near genes involved in CD4^+^ T cell activation (rs17753641 near *IL12A*, rs1518110 near *IL10*, rs7574070 near *STAT4*, rs924080 near *IL23R-IL12RB2*), while the *CCR1-CCR3* variant (rs7616215) is associated with diminished monocyte chemotaxis ([@r7][@r8]--[@r9]). Homozygous inheritance of the nonsense mutation (W143X) in *FUT2* (rs601338) among Caucasians impairs secretion of ABO antigens at mucosal surfaces ([@r13]); this and other nonsecretor alleles modulate risk not only for Behçet's disease but also for Crohn's disease and some intestinal infections ([@r14], [@r15]). In addition, we screened our cohorts for a frameshift insertion in *CARD8* (rs140826611), which was reported by another group to be significantly associated with PFAPA ([@r16]).

Patients who met the diagnostic criteria for PFAPA were included ([*SI Appendix*, *Materials and Methods*](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2002051117/-/DCSupplemental)). We initially recruited a cohort of 129 European--American individuals with PFAPA and compared their ancestry to that of individuals of European ancestry in the HapMap database ([@r17]) using genotyping data generated from the OmniExpressExome-8 (v1.4 or 1.6) chip from Illumina; 7 individuals with PFAPA who clustered away from the HapMap Caucasian cohort were excluded ([*SI Appendix*, Fig. S1](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2002051117/-/DCSupplemental)). Therefore, in total, we screened a discovery cohort of 122 European--American patients with PFAPA. We compared the frequencies of the candidate variants to those of 1,927 participants in the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort, a primarily Caucasian cohort from the United Kingdom. The frequency of the *FUT2* variant was not available in the ALSPAC cohort; therefore, the frequency among 503 Europeans in the 1000 Genomes cohort was used as the comparator. Later, we recruited a replication cohort of 64 European--American individuals with PFAPA; 4 of these individuals did not genetically cluster with individuals of European ancestry from the HapMap cohort and were excluded, and another individual was found to be identical to an individual in the discovery cohort and was excluded ([*SI Appendix*, Fig. S1](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2002051117/-/DCSupplemental)). In total, we screened a replication cohort of 59 European--American patients with PFAPA and compared the frequencies of the candidate noncoding variants to those of ∼7,700 non-Finnish Europeans in the Genome Aggregation Database (gnoMAD) and coding variants to ∼33,000 non-Finnish Europeans in the Exome Aggregation Consortium (ExAC). We also genotyped a replication cohort of 50 patients with PFAPA from Turkey and compared the allele frequencies to that of about 1,880 Turkish controls without Behçet's disease or recurrent aphthous stomatitis who were previously genotyped ([@r8], [@r9]).

Risk allele frequencies and odds ratios (ORs) in each of the three cohorts and ORs and *P* values from a metaanalysis of these three cohorts are shown in [Table 1](#t01){ref-type="table"} (additional data in [*SI Appendix*, Table S1](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2002051117/-/DCSupplemental)). A variant upstream of *IL12A* (rs17753641) was consistently the most significant variant in all three cohorts and in the metaanalysis with an OR~meta~ of 2.13 (*P*~meta~ = 6 × 10^−9^). Three additional variants near *IL10*, *STAT4*, and *CCR1-CCR3* were also significantly associated with PFAPA in the metaanalysis. Variants we queried in or near *IL23R-IL12RB2*, *FUT2*, and *CARD8* were not significantly associated with PFAPA in the metaanalysis.

###### 

Candidate gene allele frequencies in three cohorts of individuals with PFAPA and in metaanalysis of three cohorts

  SNP           Nearest gene                            Risk allele                   Risk allele frequency among PFAPA cases[\*](#tfn1){ref-type="table-fn"}   Risk allele frequency among controls[^†^](#tfn2){ref-type="table-fn"}   ORs          OR~meta~ (95% CI)   *P*~meta~   Bonferroni corrected *P*~meta~[^‡^](#tfn3){ref-type="table-fn"}
  ------------- --------------------------------------- ----------------------------- ------------------------------------------------------------------------- ----------------------------------------------------------------------- ------------ ------------------- ----------- -----------------------------------------------------------------
  rs17753641    *IL12A*                                 G                             0.21                                                                      0.12                                                                    2.03                                         
  0.22          0.12                                    2.12                          2.13                                                                                                                                                                                           
  0.10          0.04[^§^](#tfn4){ref-type="table-fn"}   2.67                          (1.67--2.72)                                                              9 × 10^−10^                                                             6 × 10^−9^                                   
  rs7574070     *STAT4*                                 A                             0.43                                                                      0.35                                                                    1.42                                         
  0.51          0.33                                    2.09                          1.51                                                                                                                                                                                           
  0.46          0.42[^¶^](#tfn5){ref-type="table-fn"}   1.16                          (1.25--1.82)                                                              2 × 10^−5^                                                              0.0001                                       
  rs1518110     *IL10*                                  A                             0.27                                                                      0.20                                                                    1.42                                         
  0.30          0.21                                    1.62                          1.45                                                                                                                                                                                           
  0.37          0.30[^§^](#tfn4){ref-type="table-fn"}   1.34                          (1.18--1.79)                                                              0.0004                                                                  0.003                                        
  rs7616215     *CCR1-CCR3*                             T                             0.72                                                                      0.65                                                                    1.39                                         
  0.69          0.62                                    1.32                          1.38                                                                                                                                                                                           
  0.73          0.66[^¶^](#tfn5){ref-type="table-fn"}   1.44                          (1.12--1.69)                                                              0.002                                                                   0.02                                         
  rs924080      *IL23R-IL12RB2*                         T                             0.58                                                                      0.53                                                                    1.25                                         
  0.57          0.55                                    1.07                          1.22                                                                                                                                                                                           
  0.68          0.61[^§^](#tfn4){ref-type="table-fn"}   1.35                          (1.00--1.47)                                                              0.04                                                                    0.3                                          
  rs601338      *FUT2*                                  Homozygous AA (nonsecretor)   0.33                                                                      0.21 (1000G, *n* = 503)                                                 1.85                                         
  0.27          0.22 (ExAC, *n* = 32934)                1.35                          1.37                                                                                                                                                                                           
  0.18          0.26[^§^](#tfn4){ref-type="table-fn"}   0.61                          (1.00--1.88)                                                              0.05                                                                    0.3                                          
  rs140826611   CARD8                                   TT insertion                  0.061                                                                     0.057                                                                   1.09                                         
  0.035         0.058 (ExAC, *n* = 33357)               0.60                          0.95                                                                                                                                                                                           
  0.050         N/A                                     N/A                           (0.59--1.52)                                                              0.83                                                                    1.0                                          

Values are listed in the following order: American discovery cohort (*n* = 122); American replication cohort (*n* = 59); Turkish replication cohort (*n* = 50).

Values are listed in the following order (unless otherwise indicated): ALSPAC (*n* = 1,927); gnoMAD (*n* ∼ 7,690); Turkish controls (*n* ∼ 1,880).

Metaanalysis *P* values (*P*~meta~) were corrected for seven comparisons using the Bonferroni correction.

Data from Takeuchi et al. ([@r9]).

Data from Kirino et al. ([@r8]).

Three patients in our cohorts who met the diagnostic criteria for PFAPA also developed additional clinical features of Behçet's disease but did not fulfill the International Study Group Criteria for Behçet's disease ([@r18]). Two patients (one in the discovery cohort and one in the European--American replication cohort) initially had regular febrile episodes with oral ulcers, cervical adenopathy, and/or tonsillar inflammation that met the diagnostic criteria for PFAPA. However, both later reported genital ulcers during some of their flares. Another Caucasian patient reported pustular and papular lesions around the anal and genital areas during febrile episodes. Thus, some patients have phenotypic features of both PFAPA and Behçet's disease, supporting the genetic similarities we find in these disease entities.

Greater Portion of Monocytes Express Both p35 and p40 during PFAPA Flares. {#s3}
--------------------------------------------------------------------------

*IL12A* encodes the p35 subunit of both the proinflammatory cytokine IL-12 and the antiinflammatory cytokine IL-35. The p35 subunit associates with p40 to form IL-12 (IL-12p70), while the p35 subunit interacts with EBI3 to form IL-35. We measured the percentage of CD14^+^ monocytes from peripheral blood mononuclear cells (PBMCs) expressing both p35 and p40 directly ex vivo from patients with PFAPA during a febrile episode (*n* = 7) and during an asymptomatic period (*n* = 12) and from healthy pediatric controls (*n* = 8). We found that during a PFAPA febrile episode, a significantly higher proportion of CD14^+^ monocytes expressed both subunits of IL-12 (p35^+^p40^+^) than those from asymptomatic periods (*P* = 0.02) and from healthy controls (*P* = 0.004) ([Fig. 1*A*](#fig01){ref-type="fig"} and [*SI Appendix*, Fig. S2](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2002051117/-/DCSupplemental)).

![Expression of IL-12p70 subunits during PFAPA flares and comparison of IL-12p70 production according to *IL12A* risk allele. During PFAPA flares, a higher percentage of patient CD14^+^ monocytes express both subunits of IL-12p70, p35 and p40, compared with nonflare periods and with healthy controls; ex vivo FACS analysis of PBMCs (*A*). Peripheral blood CD14^+^ monocytes from adults homozygous and heterozygous for the risk allele near *IL12A* (rs17753641) secrete more IL-12p70 following priming with IFN-γ and stimulation with LPS than monocytes from individuals without the risk allele; ELISA on supernatant of in vitro-stimulated cells (*B*). Each dot represents an individual. Mean and SD are plotted. \**P* \< 0.05, \*\**P* \< 0.005.](pnas.2002051117fig01){#fig01}

Monocytes from Patients Heterozygous and Homozygous for the rs17753641 Risk Allele near *IL12A* Produce More IL-12p70. {#s4}
----------------------------------------------------------------------------------------------------------------------

In order to determine whether the risk allele rs17753641 affects IL-12p70 production, we obtained PBMCs from adults from the National Institutes of Health Blood Bank and The Genomic Ascertainment Cohort (T.G.A.C.) who were homozygous for the reference allele (*n* = 25), heterozygous for the risk allele (*n* = 19), and homozygous for the risk allele (*n* = 4). We purified CD14^+^ monocytes by magnetic-activated cell sorting and primed the CD14^+^ monocytes with IFN-γ overnight and stimulated with LPS for 8 h. We found that compared to those without the risk allele, monocytes from individuals who were heterozygous or homozygous for the risk allele secreted significantly more IL-12p70 into the supernatant (*P* = 0.045 and *P* = 0.027, respectively) ([Fig. 1*B*](#fig01){ref-type="fig"}). However, no significant differences in the geometric mean fluorescence intensity of the individual intracellular subunits (p35, p40, and EBI3) were found by flow cytometry according to genotype at 8 h of stimulation ([*SI Appendix*, Fig. S3](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2002051117/-/DCSupplemental)).

*HLA-B\*15:01*, *HLA-B\*35:02*, *HLA-DPA1\*02:02*, and the Haplotype Comprised of *HLA-DRB1\*13:01*, *HLA-DQA1\*01:03*, and *HLA-DQB1\*06:03* Are Risk Alleles for PFAPA Syndrome. {#s5}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In total, 198 European--American cases and 50 Turkish cases with PFAPA were genotyped on the OmniExpressExome-8 (v1.4 or v1.6) chip from Illumina. Genotyping data were obtained from 5,437 controls of European ancestry from six dbGaP studies (study IDs are phs000652.v1.p1, phs000138.v2.p1, phs000346.v2.p2, phs000812.v1.p1, phs000331.v1.p1, and phs000168.v2.p2) and from 1,779 Turkish controls previously genotyped on the Immunochip ([@r9], [@r19]). One European--American case and 3 Turkish cases were excluded due to low genotype call rate, 1 European--American case was excluded for relatedness (identical patient), and another 11 European--American cases were excluded due to poor ancestry matching with individuals of European ancestry from the HapMap database ([*SI Appendix*, Fig. S4](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2002051117/-/DCSupplemental)). No controls of either ethnicity or Turkish PFAPA cases were excluded. In total, 185 European--American cases and 47 Turkish cases of PFAPA were analyzed. Classical *HLA* types were imputed from genotyping data from the MHC region of chromosome 6 with SNP2HLA. *HLA* alleles were converted to numeric values for regression analysis with a dominant model (1 if the allele was present, 0 if absent), and regression analyses were corrected for the top 10 principal components comparing genotypes of cases and controls in each population ([*SI Appendix*, Fig. S5](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2002051117/-/DCSupplemental)).

Among European--Americans, the classical *HLA* types with dominant allele frequency greater than 5% that were most significantly associated with PFAPA were *HLA-B\*15:01* (OR 2.00, *P* = 0.001), *HLA-C\*08:02* (OR 0.29, *P* = 0.002), *HLA-B\*35:02* (OR = 3.61, *P* = 0.003) ([*SI Appendix*, Table S2](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2002051117/-/DCSupplemental)). The following three class II alleles were also among the top 10 most significant alleles associated with PFAPA: *HLA-DRB1\*13:01*, *HLA-DQA1\*01:03*, and *HLA-DQB1\*06:03*. Among Turkish individuals, the most significant risk alleles were *HLA-DQB1\*06:03* (OR 3.32, *P* = 0.002) and *HLA-DRB1\*13:01* (OR 2.97, *P* = 0.005) ([*SI Appendix*, Table S3](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2002051117/-/DCSupplemental))

The 10 most significant *HLA* allele associations with dominant allele frequency greater than 5% among the European--American cohort were assessed in a metaanalysis of both the Turkish and European--American cohorts. In the metaanalysis, *HLA-DQB1\*06:03*, *HLA-DRB1\*13:01*, *HLA-DQA1\*01:03*, *HLA-B\*15:01*, *HLA-B\*35:02*, and *HLA-DPA1\*02:02* were significant risk alleles for PFAPA ([Table 2](#t02){ref-type="table"}). Conditional analyses and linkage analysis on Haploview showed that *HLA-DRB1\*13:01*, *HLA-DQA1\*01:03*, and *HLA-DQB1\*06:03* are in LD and comprise a haplotype ([*SI Appendix*, Fig. S6 and Tables S2 and S3](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2002051117/-/DCSupplemental)).

###### 

Classical *HLA* allele associations in cohorts of European and Turkish ancestry and metaanalyses of these two cohorts

  Classical *HLA* type                                                                 Frequency of dominant genotype among PFAPA cases[\*](#tfn6){ref-type="table-fn"}   Frequency of dominant genotype among controls[^†^](#tfn7){ref-type="table-fn"}   OR      *P* value   OR~meta~ (95% CI)   *P*~meta~    Bonferroni corrected *P*~meta~[^‡^](#tfn8){ref-type="table-fn"}
  ------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------- -------------------------------------------------------------------------------- ------- ----------- ------------------- ------------ -----------------------------------------------------------------
  *HLA-DQB1*[\*](#tfn6){ref-type="table-fn"}*06:03*[^§^](#tfn9){ref-type="table-fn"}   0.18                                                                               0.12                                                                             1.83    0.006       2.13 (1.50--3.03)   2 × 10^−5^   0.0002
  0.28                                                                                 0.11                                                                               3.32                                                                             0.002                                                
  *HLA-DRB1*[\*](#tfn6){ref-type="table-fn"}*13:01*[^§^](#tfn9){ref-type="table-fn"}   0.18                                                                               0.12                                                                             1.79    0.008       2.04 (1.43--2.91)   9 × 10^−5^   0.0009
  0.26                                                                                 0.11                                                                               2.97                                                                             0.005                                                
  *HLA-DQA1*[\*](#tfn6){ref-type="table-fn"}*01:03*[^§^](#tfn9){ref-type="table-fn"}   0.20                                                                               0.13                                                                             1.83    0.004       1.97 (1.40--2.77)   0.0001       0.001
  0.32                                                                                 0.17                                                                               2.44                                                                             0.015                                                
  *HLA-B*[\*](#tfn6){ref-type="table-fn"}*15:01*                                       0.19                                                                               0.13                                                                             2.00    0.001       1.96 (1.33--2.89)   0.0007       0.007
  0.043                                                                                0.035                                                                              1.48                                                                             0.62                                                 
  *HLA-B*[\*](#tfn6){ref-type="table-fn"}*35:02*                                       0.05                                                                               0.01                                                                             3.61    0.003       2.86 (1.56--5.26)   0.0007       0.007
  0.13                                                                                 0.07                                                                               1.88                                                                             0.24                                                 
  *HLA-DPA1*[\*](#tfn6){ref-type="table-fn"}*02:02*                                    0.12                                                                               0.06                                                                             2.03    0.01        1.93 (1.23--3.04)   0.004        0.04
  0.11                                                                                 0.08                                                                               1.61                                                                             0.36                                                 

Values are listed in the following order: Caucasian cases (*n* = 185); Turkish cases (*n* = 47).

Values are listed in the following order: Caucasian controls (*n* = 5,437); Turkish controls (*n* = 1,779). *HLA* types of the 5437 Caucasian controls were previously reported in Gourh et al. ([@r19]).

Metaanalysis *P* values (*P*~meta~) were corrected for 10 comparisons with Bonferroni correction.

These *HLA* alleles are in LD.

Discussion {#s6}
==========

In this study, we found that common variants previously associated with two other disorders characterized by aphthous ulcers (Behçet's disease and recurrent aphthous stomatitis) are also strongly associated with PFAPA ([Table 3](#t03){ref-type="table"}). The genetic similarities among these three diseases suggest that they share features of their pathogenesis and could be placed on a continuum. We propose grouping these diseases as a family called Behçet's spectrum disorders (BSDs). The BSDs span recurrent aphthous ulcers as the mildest, PFAPA as the intermediary, and Behçet's disease as the most severe ([Fig. 2](#fig02){ref-type="fig"}).

###### 

Genetic similarities among PFAPA, recurrent aphthous stomatitis, and Behçet's disease

                                                                                 Recurrent aphthous stomatitis (RAS)                                                   PFAPA         Behçet's disease                                                                                                                                                                                                                                                                 
  ------------------------------------------------------------------------------ ------------------------------------------------------------------------------------- ------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- ----------------------------------------------------------------------------------- ------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *IL12A*                                                                        rs76830965[\*](#tfn10){ref-type="table-fn"}                                           0.72          rs17753641                                                                                                                                                              2.13          rs17753641[^†^](#tfn11){ref-type="table-fn"}                                        1.90   ORs for rs17753641 and rs76830965 are reported for opposite alleles. Risk alleles for these two SNPs are in high LD with each other (D′=1, *r*^2^ = 1).
  4 × 10^−483^                                                                   6 × 10^−9^                                                                            1 × 10^−9^                                                                                                                                                                                                                                                                                     
  *STAT4*                                                                        rs11684030[\*](#tfn10){ref-type="table-fn"}                                           1.06          rs7574070                                                                                                                                                               1.51          rs7574070[‡](#tfn12){ref-type="table-fn"}                                           1.27   rs7574070 and rs11684030 are in high LD with each other (D′=0.99, *r*^2^ = 0.93).
  1 × 10^−42^                                                                    1 × 10^−4^                                                                            1 × 10^−9^                                                                                                                                                                                                                                                                                     
  *IL10*                                                                         rs1800871[\*](#tfn10){ref-type="table-fn"}                                            1.18          rs1518110                                                                                                                                                               1.45          rs1518110[^†^](#tfn11){ref-type="table-fn"}                                         1.34   rs1518110 and rs1800871 are in high LD with each other (D′=0.98, *r*^2^ = 0.89).
  6 × 10^−236^                                                                   0.003                                                                                 5 × 10^−9^                                                                                                                                                                                                                                                                                     
  *CCR1-CCR3*                                                                    rs4493469[\*](#tfn10){ref-type="table-fn"}                                            1.10          rs7616215                                                                                                                                                               1.38          rs7616215[^†^](#tfn11){ref-type="table-fn"}                                         1.40   Several variants near the *CCR3* and/or *CCR1* loci are associated with RAS.
  2 × 10^−43^                                                                    0.02                                                                                  1 × 10^−10^                                                                                                                                                                                                                                                                                    
  *IL23R-IL12RB2*                                                                Not reported as a top association[\*](#tfn10){ref-type="table-fn"}                                  Not significant                                                                                                                                                                       rs924080[^†^](#tfn11){ref-type="table-fn"}                                          1.28   
  3 × 10^−7^                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  *FUT2*                                                                         Not reported as a top association[\*](#tfn10){ref-type="table-fn"}                                  Not significant                                                                                                                                                                       rs601338[^†^](#tfn11){ref-type="table-fn"}                                          1.52   
  7 × 10^−9^                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  *HLA*                                                                          *HLA-DRB1*[\*](#tfn10){ref-type="table-fn"}*01:03*[\*](#tfn10){ref-type="table-fn"}   1.33          *HLA-DQB1*[\*](#tfn10){ref-type="table-fn"}*06:03* (in LD with *HLA-DRB1*[\*](#tfn10){ref-type="table-fn"}*13:01 & HLA-DQA1*[\*](#tfn10){ref-type="table-fn"}*01:03)*   2.13          *HLA-B*[\*](#tfn10){ref-type="table-fn"}*51:01*[^§^](#tfn13){ref-type="table-fn"}   3.3    In Behçet's disease, *HLA-B*[\*](#tfn10){ref-type="table-fn"}*15:01* was nearly significant in conditional analyses. *HLA-B*[\*](#tfn10){ref-type="table-fn"}*15* was statistically significant among Behçet's disease patients without *HLA-B*[\*](#tfn10){ref-type="table-fn"}*51* (OR 2.0, *P* = 3 × 10^−5^).[^§^](#tfn13){ref-type="table-fn"}
  2.0 × 10^−24^                                                                  *HLA-B*[\*](#tfn10){ref-type="table-fn"}*15:01*                                       0.0002        *HLA-B*[\*](#tfn10){ref-type="table-fn"}*15:01*[^§^](#tfn13){ref-type="table-fn"}                                                                                       5 × 10^−58^                                                                                              
  HLA-B[\*](#tfn10){ref-type="table-fn"}15:01[\*](#tfn10){ref-type="table-fn"}   1.10                                                                                  1.96          1.24                                                                                                                                                                                                                                                                             
  6.4 × 10^−9^                                                                   0.007                                                                                 0.2                                                                                                                                                                                                                                                                                            

LD, linkage disequilibrium, reported in HaploReg 4.1 for the 1000G Phase 1 EUR population.

Data from Dudding et al. ([@r12]).

Data from Takeuchi et al. ([@r9]).

Data from Kirino et al. ([@r8]).

Data from Ombrello et al. ([@r11]).

![The BSDs include recurrent aphthous stomatitis, PFAPA, and Behçet's disease. Recurrent aphthous ulcers are on the mild end of the spectrum with relatively weak *HLA* associations, while Behçet\'s disease has the most severe disease manifestations and strongest *HLA* associations, and PFAPA is between the two.](pnas.2002051117fig02){#fig02}

Clinically, patients who exhibit features of more than one of these disease entities have been described. Many adults with Behçet's disease have reported symptoms earlier in childhood that fulfill the diagnostic criteria for PFAPA ([@r3], [@r20]). Two patients in our cohort reported genital ulcers during fever flares, and similar patients have been reported in the literature ([@r21], [@r22]). In light of these findings, it is possible that patients with bipolar or complex aphthosis also fall on this spectrum. On the milder end of the spectrum, patients with PFAPA are significantly more likely to have first-degree family members with recurrent aphthous ulcers ([@r5]). Patients who resist classification with existing disease entities may better be referred to as having a BSD.

Although these aphthous ulcer disorders have overlapping genetic risk factors and clinical features, differences in the severity and tissue involvement of these diseases necessitate investigation of additional factors that influence the ultimate phenotype of an individual. Our results suggest that MHC may be one of these factors. Although *HLA-B\*15* has been identified as a significant risk allele for all three diseases ([@r11], [@r12]), other significant *HLA* associations are distinct for each disease ([Table 3](#t03){ref-type="table"}). In Behçet's disease, *HLA-B\*51* is the most significant risk factor for the disease, but other class I *HLA* alleles also contribute relatively weakly. For recurrent aphthous ulcers, the most significant MHC association among Caucasians is a rare class II allele, *HLA-DRB1\*01:03*, but other more common class I and class II alleles also contribute to risk, many of which are distinct from those associated with Behçet's disease. In PFAPA, we found both class I and class II *HLA* associations. Aside from *HLA-B\*15*, the other risk alleles we found appear to be uniquely associated with PFAPA. This suggests that the presence of particular *HLA* types, which affects antigen presentation to and thereby activation of T cells, may play a role in determining the phenotype of the patient.

In addition, the strength of *HLA* associations is different in each of these diseases. In Behçet's disease, class I *HLA* associations are the major risk alleles for the disease with considerably stronger and more significant disease associations than the non-MHC genomic variants; the strongest risk allele, *HLA-B\*51*, increases the odds of having Behçet's disease by three- to sevenfold in most studies ([@r7], [@r11], [@r23]). On the other hand, in recurrent aphthous stomatitis, non-MHC genomic variants appear to play a stronger role. Although the *HLA-DRB1\*01:03* allele had an OR of 1.33, other more common class I and class II alleles had weaker contributions to the disease, with ORs between 1.05 and 1.12 ([@r12]). In the European--American PFAPA cohort we assessed, we found that the class I and class II *HLA* associations increase the odds of having PFAPA by about twofold, which is stronger than in recurrent aphthous stomatitis and weaker than in Behçet's disease, with the caveat that these association studies were performed in different populations.

The BSDs exhibit differences in organ involvement. For example, in contrast to individuals with PFAPA and recurrent aphthous stomatitis, those with Behçet's disease may present with vascular and ocular disease. A GWAS of PFAPA would facilitate a deeper characterization of the genetic architecture of the disease, allowing us to compare the attributable risk of *HLA* and non-*HLA* susceptibility loci and identify differences in genetic risk loci that modulate phenotype among the BSDs. In addition to genetic risk loci, other factors---such as the microbiome, nutritional deficits, and age of the individual---may also influence disease manifestations.

The strongest susceptibility loci for PFAPA that we found (rs17753641) is located in a regulatory region 50,000 bases upstream of the *IL12A* gene, which encodes the p35 subunit of the cytokines IL-12 and IL-35. IL-12 is produced primarily by antigen-presenting cells and is a major promoter of CD4^+^ T helper 1 (Th1) cell polarization and induction of IFN-γ production by Th1 cells, CD8^+^ T cells, and NK cells ([@r24]). We found that rs17753641 is associated with increased IL-12p70 production from monocytes upon stimulation, suggesting that individuals with this variant are prone to excess Th1 cell activation. IL-35 is an antiinflammatory cytokine produced by induced T regulatory cells, B cells, and tolerogenic dendritic cells ([@r25][@r26][@r27][@r28]--[@r29]); the role of this susceptibility variant in regulating IL-35 production remains unknown.

Some of the other risk alleles that we found for PFAPA also affect antigen-presenting cell function and CD4^+^ T cell activation. The risk SNP near *IL10* has previously been associated with reduced IL-10 production from monocytes, which may augment the effects of proinflammatory mediators like IL-12 and IL-23 ([@r7]). The susceptibility allele near *STAT4* is associated with elevated *STAT4* mRNA expression ([@r8]), which presumably would enhance signaling from IL-12, IL-23, and type 1 IFN stimulation in CD4^+^ T cells ([@r30]). On the other hand, the susceptibility SNP near *CCR1-CCR3* is correlated with a reduction in *CCR1* expression and reduced monocyte migration in response to MIP-1α, which may diminish mucosal barrier function ([@r8]). Other studies indicate that *CCR1* expression is higher among M2 macrophages, which have regulatory roles, and so the risk variant may disproportionately decrease M2 macrophage migration to sites of inflammation ([@r31]). Another study suggested that this variant more prominently increases *CCR2* expression, thereby increasing monocyte migration to sites of inflammation ([@r32]). In aggregate, these risk alleles likely render individuals more susceptible to abnormal innate-immune cell function and heightened T cell activation. Further studies are necessary to understand the role of these risk variants and *HLA* alleles in the periodicity of PFAPA.

In concordance with the predicted effects of the genomic variants we identified and in line with our finding of more p35^+^p40^+^ monocytes during flares, immunologic profiling of peripheral blood during febrile PFAPA episodes indicates heightened monocyte and Th1 activation with up-regulation of IFN-induced transcripts and increased levels of IL-12, IFN-γ, and Th1-associated chemokines during flares ([@r33][@r34][@r35]--[@r36]). Elevated expression of Th1-associated chemokines was also noted in the tonsils of patients with PFAPA ([@r37]). Similarly, in both Behçet's disease and recurrent aphthous stomatitis, heightened Th1 and Th17 activation have been noted in both the peripheral blood and around ulcerative lesions ([@r38][@r39][@r40][@r41][@r42]--[@r43]).

Our comparisons of genetic risk alleles for PFAPA, Behçet's disease, and recurrent aphthous ulcers begin to build a framework for understanding the genetic architecture of ulcerative diseases of the oropharynx. The overlap in genetic susceptibility loci may also extrapolate to treatment strategies. Apremilast, a phosphodiesterase 4 inhibitor, has been shown to be effective in reducing the number of aphthous ulcers in patients with Behçet's disease and a small number of individuals with treatment-refractory recurrent aphthous stomatitis ([@r44][@r45]--[@r46]). Because apremilast reduces production of proinflammatory cytokines, including IL-12p70 and IFN-γ from human PBMCs, it may have efficacy in treating patients with PFAPA ([@r47], [@r48]). In addition, because IL-12 has significance in the pathogenesis of PFAPA, ustekinumab, a monoclonal antibody targeting the p40 subunit of IL-12 and IL-23, may be a potential therapy for treatment-refractory cases. Clinical trials of these medications for PFAPA would provide more information.

Materials and Methods {#s7}
=====================

Detailed descriptions of patient recruitment, genotyping, ancestry analysis, *HLA* typing, and assessment of IL-12p70 production from human peripheral blood cells are provided in [*SI Appendix*](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2002051117/-/DCSupplemental). This study was approved by the institutional review boards at the National Institutes of Health (Bethesda, MD), Children's Hospital Boston (Boston, MA), Vanderbilt University School of Medicine (Nashville, TN), and Hacettepe University Faculty of Medicine (Ankara, Turkey). All subjects with PFAPA and/or their parents gave consent for participation in this study.

Data Availability. {#s8}
------------------

The candidate SNP genotyping data for discovery and replication cohorts are in [Dataset S1](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2002051117/-/DCSupplemental). Genotyping data for the classical *HLA* alleles for European--American and Turkish cases and controls are in [Dataset S2](https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2002051117/-/DCSupplemental); data are coded according to the dominant model (1 if allele is present and 0 if allele is not present).
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